AgomAb Therapeutics NV
Latest round
- Series D
Last raised
- Nov 2024
Total raised
- $322M
Investors
- 18
About AgomAb Therapeutics NV
Based in Belgium, AgomAb Therapeutics NV is a biopharmaceutical company focused on developing innovative therapies for restoring organ function and treating fibrotic diseases. AgomAb Therapeutics NV, founded in 2017 in Ghent, Belgium, specializes in creating therapies for fibrotic diseases.USD 16 per share per share at Nasdaq, under the ticker "AGMB". As of March 2026, Tim Knotnerus serves as Chief Executive Officer. AgomAb Therapeutics NV develops innovative therapies specifically targeting fibrotic diseases. Its lead product, AGMB-129, is an oral small molecule inhibitor aimed at treating Fibrostenosing Crohn’s Disease (FSCD), currently undergoing clinical testing in the STENOVA1 Phase 2a trial across the USA, Canada, and Europe.
Who invested in AgomAb Therapeutics NV
18 investors across 6 rounds
See all investors in AgomAb Therapeutics NV
Sign up free to see every VC on the cap table, the rounds they joined, and how much each round raised.
Questions about AgomAb Therapeutics NV
Who invested in AgomAb Therapeutics NV?
AgomAb Therapeutics NV has 18 investors on record across 6 venture rounds. Sign up free to see every VC on the cap table and the rounds they joined.
How much funding has AgomAb Therapeutics NV raised?
AgomAb Therapeutics NV has raised 6 venture rounds. Sign up free to see how much each round raised and the total.
When did AgomAb Therapeutics NV last raise money?
AgomAb Therapeutics NV's most recent round on record is a Series D, in Nov 2024.
What does AgomAb Therapeutics NV do?
Based in Belgium, AgomAb Therapeutics NV is a biopharmaceutical company focused on developing innovative therapies for restoring organ function and treating fibrotic diseases.
Where is AgomAb Therapeutics NV headquartered?
AgomAb Therapeutics NV is headquartered in Antwerpen, Belgium.
Which VCs invest in companies like AgomAb Therapeutics NV?
Among active investors with capital left to deploy, Index Ventures, Forbion, European Investment Bank and Generation Investment Management back biotechnology companies at AgomAb Therapeutics NV's stage. Their profiles are linked below.
VCs backing biotechnology startups at Series D
Raising like AgomAb Therapeutics NV? Find the right VCs.
Capital Atlas matches your startup to active investors by stage, sector and region.